^
    10d
    KEYNOTE-D35: Oral Axl/Mer/CSF1R Selective Tyrosine Kinase Inhibitor Q702 in Combination With Pembrolizumab in Patients With Selected Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=120, Active, not recruiting, Qurient Co., Ltd. | Recruiting --> Active, not recruiting | Trial completion date: Jun 2026 --> Mar 2028 | Trial primary completion date: Oct 2025 --> Dec 2027
    Enrollment closed • Trial completion date • Trial primary completion date
    |
    Keytruda (pembrolizumab) • adrixetinib (Q702)
    17d
    QRNT-012: Study of Q702 in Subjects with Relapsed or Refractory Chronic Graft-versus-Host Disease (cGVHD) (2025-522680-14-00)
    P1, N=16, Recruiting, Qurient Co. Ltd.
    New P1 trial
    |
    adrixetinib (Q702)
    2ms
    A Study to Evaluate Adrixetinib (Q702) in Adults With Active Chronic Graft-Versus-Host Disease (clinicaltrials.gov)
    P1, N=18, Recruiting, Qurient Co., Ltd. | Not yet recruiting --> Recruiting
    Enrollment open
    |
    adrixetinib (Q702)
    2ms
    Oral Axl/Mer/CSF1R Selective Tyrosine Kinase Inhibitor in Patients With Advanced Solid Tumor (clinicaltrials.gov)
    P1, N=51, Completed, Qurient Co., Ltd. | Active, not recruiting --> Completed | N=78 --> 51 | Trial completion date: Feb 2025 --> Dec 2025 | Trial primary completion date: Dec 2024 --> Dec 2025
    Trial completion • Enrollment change • Trial completion date • Trial primary completion date
    |
    adrixetinib (Q702)
    7ms
    A Study to Evaluate Adrixetinib (Q702) in Adults With Active Chronic Graft-Versus-Host Disease (clinicaltrials.gov)
    P1, N=18, Not yet recruiting, Qurient Co., Ltd.
    New P1 trial
    |
    adrixetinib (Q702)
    1year
    Phase I Study of Q702 with Azacitidine and Venetoclax for Relapsed or Refractory Acute Myeloid Leukemia (clinicaltrials.gov)
    P1, N=32, Recruiting, M.D. Anderson Cancer Center | Not yet recruiting --> Recruiting | Initiation date: Nov 2025 --> Feb 2025
    Enrollment open • Trial initiation date
    |
    Venclexta (venetoclax) • azacitidine • adrixetinib (Q702)
    1year
    Phase I Study of Q702 With Azacitidine and Venetoclax for Relapsed or Refractory Acute Myeloid Leukemia (clinicaltrials.gov)
    P1, N=32, Not yet recruiting, M.D. Anderson Cancer Center | Initiation date: Nov 2024 --> Nov 2025 | Trial primary completion date: Jul 2026 --> Jul 2027
    Trial initiation date • Trial primary completion date
    |
    Venclexta (venetoclax) • azacitidine • adrixetinib (Q702)
    over1year
    Oral Axl/Mer/CSF1R Selective Tyrosine Kinase Inhibitor in Patients with Advanced Solid Tumor (clinicaltrials.gov)
    P1, N=78, Active, not recruiting, Qurient Co., Ltd. | Recruiting --> Active, not recruiting
    Enrollment closed • Metastases
    |
    adrixetinib (Q702)
    almost2years
    Phase I Study of Q702 With Azacitidine and Venetoclax for Relapsed or Refractory Acute Myeloid Leukemia (clinicaltrials.gov)
    P1, N=32, Not yet recruiting, M.D. Anderson Cancer Center
    New P1 trial
    |
    Venclexta (venetoclax) • azacitidine • adrixetinib (Q702)
    almost2years
    Oral Axl/Mer/CSF1R Selective Tyrosine Kinase Inhibitor Q702 in Combination With Pembrolizumab in Patients With Selected Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=120, Recruiting, Qurient Co., Ltd. | Phase classification: P1b/2 --> P1/2
    Phase classification • Combination therapy • Metastases
    |
    Keytruda (pembrolizumab) • adrixetinib (Q702)
    2years
    Oral Axl/Mer/CSF1R Selective Tyrosine Kinase Inhibitor in Patients With Advanced Solid Tumor (clinicaltrials.gov)
    P1, N=78, Recruiting, Qurient Co., Ltd. | Trial completion date: Nov 2023 --> Feb 2025 | Trial primary completion date: Jul 2023 --> Dec 2024
    Trial completion date • Trial primary completion date • Metastases
    |
    adrixetinib (Q702)
    almost3years
    Patient pharmacodynamic biomarker and pk evaluation results from an ongoing phase I dose-escalation study of q702, an axl, mer and csf1r kinase inhibitor in patients with advanced solid tumors (AACR 2023)
    Up to 240 mg, Q702 has demonstrated the intended pharmacologic activity with acceptable safety profile. In biomarker analysis, immune modulation activity is exerted by Axl/Mer/CSF1R inhibition. Further assessment of pharmacokinetics, pharmacodynamics, safety and antitumor activity will be performed at the expansion phase at the RP2D in patients with selected advanced tumors.
    Clinical • P1 data • PK/PD data • Metastases
    |
    CD8 (cluster of differentiation 8) • AXL (AXL Receptor Tyrosine Kinase)
    |
    adrixetinib (Q702)